A Trial of Intra-pleuraL bacterial immuno-Therapy in mesothelioma (TILT): A feasibility study using the 'trial within a cohort' methodology
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 08 Jan 2019
At a glance
- Drugs Picibanil (Primary)
- Indications Mesothelioma
- Focus Adverse reactions
- Acronyms TILT
- 06 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2018 Planned number of patients changed from 48 to 24.
- 12 Dec 2017 New trial record